Alemtuzumab Improves Brain MRI Outcomes in Patients With Active Relapsing-Remitting Multiple Sclerosis: 3-Year Follow-up of the CARE-MS Studies

被引：0
|
作者：
Arnold, Douglas
Cohen, Jeffrey
Barkhof, Frederik
Selmaj, Krzysztof
Margolin, David
Palmer, Jeffrey
Fox, Edward
机构：
来源：
NEUROLOGY | 2014年 / 83卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E35 / E36
页数：2
相关论文
共 50 条
  • [41] Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis
    Graves, Jennifer
    Galetta, Steven L.
    Palmer, Jeffrey
    Margolin, David H.
    Rizzo, Marco
    Bilbruck, John
    Balcer, Laura J.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (10) : 1302 - 1309
  • [42] Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study
    Amato, Maria P.
    Portaccio, Emilio
    Goretti, Benedetta
    Zipoli, Valentina
    Iudice, Alfonso
    Della Pina, Dario
    Malentacchi, Gianmichele
    Sabatini, Simonetta
    Annunziata, Pasquale
    Falcini, Mario
    Mazzoni, Monica
    Mortilla, Marzia
    Fonda, Claudio
    De Stefano, Nicola
    MULTIPLE SCLEROSIS, 2010, 16 (12): : 1474 - 1482
  • [43] Alemtuzumab Improves Contrast Sensitivity in Relapsing-Remitting Multiple Sclerosis Patients
    Balcer, Laura
    Galetta, Steven
    Maguire, Maureen
    Palmer, Jeffrey
    Margolin, David
    Rizzo, Marco
    NEUROLOGY, 2011, 76 (09) : A446 - A446
  • [44] Quality of life improvements in patients with active relapsing-remitting multiple sclerosis are not impacted by acute infections after receiving alemtuzumab in CARE-MS II
    Vermersch, P.
    Giovannoni, G.
    Cohen, J. A.
    Moreau, T.
    Wray, S.
    Margolin, D. H.
    Kasten, L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 621 - 621
  • [45] Alemtuzumab suppresses MRI disease activity over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy (CARE-MS II)
    Traboulsee, A.
    Barnett, M.
    Comi, G.
    De Seze, J.
    Giovannoni, G.
    Pelletier, D.
    Rovira, A.
    Schippling, S.
    Margolin, D. H.
    Thangavelu, K.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 641 - 642
  • [46] Two-year follow-up of 19 patients treated with alemtuzumab for active relapsing-remitting MS: the Lyon's experience
    Durand-Dubief, F.
    Marignier, R.
    Ionescu, I.
    Pique, J.
    Lavie, C.
    Vukusic, S.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 848 - 848
  • [47] Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)
    Oreja-Guevara, C.
    Alroughani, R.
    Brassat, D.
    Boyko, A. N.
    McCombe, P.
    Steingo, B.
    Van Wijmeersch, B.
    Margolin, D. H.
    Thangavelu, K.
    Rodriguez, C. E.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 648 - 649
  • [48] Characterization of the Peripheral Blood Transcriptome in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients From the CARE-MS I and II Studies
    Zhang, Mindy
    Chang, Yi-Chien
    Shankara, Srinivas
    Jacobs, Alan
    Godin, Jean
    Klinger, Katherine
    Madden, Stephen
    NEUROLOGY, 2019, 92 (15)
  • [49] Alemtuzumab-treated patients with relapsing-remitting MS show low rates of conversion to secondary progressive MS: 6-year follow-up of CARE-MS I and II
    Horakova, D.
    Boster, A.
    Bertolotto, A.
    Freedman, M.
    Goelz, S.
    Firmino, I.
    Cavalier, S.
    Thangavelu, K.
    Margolin, D. H.
    Ziemssen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 632 - 633
  • [50] Lymphocyte depletion and repopulation is consistent across alemtuzumab treatment courses in patients with relapsing-remitting multiple sclerosis: 6-year analysis of patients from the CARE-MS studies
    Boyko, A. N.
    Havrdova, E.
    King, J.
    Limmroth, V.
    Selmaj, K. W.
    Sharrack, B.
    Vermersch, P.
    Margolin, D. H.
    Chou, E.
    Wray, S.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 312 - 313
12345